Iodine seed prostate brachytherapy: An alternative first-line choice for early prostate cancer

Prostate Cancer and Prostatic Diseases

Volumn 7, Issue 3, 2004, Pages 201-207

  Langley, Stephen E M ^a   Laing, R W ^a  

^a ROYAL SURREY COUNTY HOSPITAL   (United Kingdom)

Author keywords

Brachytherapy; Cancer; Iodine seed; Prostate

Indexed keywords

ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; BICALUTAMIDE; GONADORELIN DERIVATIVE; GOSERELIN; IODINE 125; PALLADIUM 103; PROSTATE SPECIFIC ANTIGEN; RAPID STRAND; RADIOACTIVE IODINE;

BEAM THERAPY; CANCER ADJUVANT THERAPY; CANCER HORMONE THERAPY; CANCER SURVIVAL; EARLY CANCER; ERECTILE DYSFUNCTION; HUMAN; MALE; OBSTRUCTIVE UROPATHY; PATIENT SELECTION; PRIORITY JOURNAL; PROCTITIS; PROSTATE CANCER; PROSTATECTOMY; QUALITY OF LIFE; RADIATION DOSE; RADIATION INJURY; RADIOISOTOPE THERAPY; RECTUM DISEASE; REPRODUCIBILITY; REVIEW; SEXUAL DYSFUNCTION; TREATMENT OUTCOME; UNITED KINGDOM; UNITED STATES; URINARY TRACT DISEASE; URINE INCONTINENCE; URINE RETENTION; ADJUVANT THERAPY; BRACHYTHERAPY; PROSTATE TUMOR;

BRACHYTHERAPY; HUMANS; IODINE RADIOISOTOPES; MALE; NEOADJUVANT THERAPY; PATIENT SELECTION; PROSTATIC NEOPLASMS; REPRODUCIBILITY OF RESULTS;

EID: 16644396306     PISSN: 13657852     EISSN: 14765608     Source Type: Journal    
DOI: 10.1038/sj.pcan.4500727     Document Type: Review

References (61)

1. Holm HH et al. Transperineal 125iodine seed implantation in prostatic cancer guided by transrectal ultrasonography. J Urol 1983; 130: 283-286.
2. Zelefsky MJ, Whitmore Jr WF. Long-term results of retropubic permanent 125iodine implantation of the prostate for clinically localized prostatic cancer. J Urol 1997; 158: 23-29, discussion 29-30.
3. Cha CM et al. Isotope selection for patients undergoing prostate brachytherapy. Int J Radiat Oncol Biol Phys 1999; 45: 391-395.
4. Wallner K et al. 1-125 vs Pd-103 for low-risk prostate cancer: Morbidity outcomes from a prospective randomized multicenter trial. Cancer J 2002; 8: 67-73.
5. Grimm PD, Blasko JC, Ragde H. Ultrasound-guided transperineal implantation of iodine-125 and palladium-103 in the treatment of early stage prostate cancer. Technical concepts in planning, operative technique and evaluation. Urol Clin North Am 1994; 2: 113-125.
6. Ragde H et al. Ten-year disease free survival after transperineal sonography-guided iodine-125 brachytherapy with or without 45-gray external beam irradiation in the treatment of patients with clinically localized, low to high Gleason grade prostate carcinoma. Cancer 1998; 83: 989-1001.
7. Grimm PD et al. 10-year biochemical (prostate-specific antigen) control of prostate cancer with (125)I brachytherapy. Int J Radiat Oncol Biol Phys 2001; 51: 31-40.
8. Blasko JC et al. The role of external beam radiotherapy with I-125/ Pd-103 brachytherapy for prostate carcinoma. Radiother Oncol 2000; 57: 273-278.
9. Sylvester JE et al. Ten-year biochemical relapse-free survival after external beam radiation and brachytherapy for localized prostate cancer: the Seattle experience. Int J Radiat Biol 2003; 57: 944-952.
10. Potters L et al. Importance of implant dosimetry for patients undergoing prostate brachytherapy. Urology 2003; 62: 1073-1077.
11. Ragde H, Gardo GL, Nadir B. Brachytherapy for clinically localized prostate cancer: Thirteen year disease-free survival of 769 consecutive prostate cancer patients with permanent implants alone. Arch Esp Urol 2001; 54: 739-747.
12. Potters L et al. Risk profiles to predict PSA relapse-free survival for patients undergoing permanent prostate brachytherapy. Cancer J Sci Am 1999; 5: 301-306.
13. Zelefsky MJ et al. Five-year biochemical outcome and toxicity with transperineal CT-planned permanent 1-125 prostate implantation for patients with localized prostate cancer. Int J Radiat Oncol Biol Phys 2000; 47: 1261-1266.
14. Lederman GS et al. Retrospective stratification of a consecutive cohort of prostate cancer patients treated with a combined regimen of external-beam radiotherapy and brachytherapy. Int J Radiat Oncol Biol Phys 2001; 49: 1297-1303.
15. Peschel R, Han S, Colberg J. Ultrasound guided transperineal implant (IMP) vs radical prostatectomy for early prostate cancer. Int J Radiat Biol 2001; 51 (Suppl 1): 292.
16. Kollmeier M, Stock R, Stone N. Biochemical outcomes after prostate brachytherapy with 5-year minimal follow-up: Importance of patient selection and implant quality. Int J Radiat Biol 2003; 57: 645-653.
17. D'Amico AV et al. Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. JAMA 1998; 280: 969-974.
18. Lee LN, Stock RG, Stone NN. Role of hormonal therapy in the management of intermediate- to high-risk prostate cancer treated with permanent radioactive seed implantation. Int J Radiat Oncol Biol Phys 2002; 52: 444-452.
19. Kwok Y et al. Risk group stratification in patients undergoing permanent (125)I prostate brachytherapy as monotherapy. Int J Radiat Oncol Biol Phys 2002; 53: 588-594.
20. Merrick GS et al. Biochemical outcome for hormone-naive patients with Gleason score 3+4 vs 4+3 prostate cancer undergoing permanent prostate brachytherapy. Urology 2002; 60: 98-103.
21. Potters L et al. A comprehensive and novel predictive modeling technique using detailed pathology factors in men with localized prostate carcinoma. Cancer 2002; 95: 1451-1456.
22. Brachman DG et al. Failure-free survival following brachytherapy alone or external beam irradiation alone for T1-2 prostate tumors in 2222 patients: Results from a single practice. Int J Radiat Oncol Biol Phys 2000; 48: 111-117.
23. Bottomley DM, Ash D. Prostate Brachytherapy Leeds 7 year results, B.S.o. Oncology Birmingham 2003.
24. Blasko JC et al. Palladium-103 brachytherapy for prostate carcinoma. Int J Radiat Oncol Biol Phys 2000; 46: 839-850.
25. Davis BJ et al. The radial distance of extraprostatic extension of prostate carcinoma: Implications for prostate brachytherapy. Cancer 1999; 85: 2630-2637.
26. Henderson A, Langley SEM, Laing R. Is bicalutamide equivalent to goserelin for prostate volume reduction before radiation therapy? A prospective observational study. Clin Oncol 2003; 15: 318-321.
27. Pilepich MV, Winter K, John MJ. Phase III radiation therapy oncology group (RTOG) trial 86-10 of androgen deprivation adjuvant to definitive radiotherapy in locally advanced prostate cancer. Int J Radiat Biol 2001; 50: 1243-1252.
28. Horwitz E et al. Subset analysis of RTOG 85-31 and 86-10 indicated an advantage for long-term vs short-term adjuvant hormones for patients with locally advanced nonmetastatic prostate cancer treated with radiation therapy. Int J Radiat Biol 2001; 49: 947-956.
29. Sylvester J et al. Short-course androgen ablation combined with external-beam radiation therapy and low-dose-rate permanent brachytherapy in early-stage prostate cancer: A matched subset analysis. Mol Urol 2000; 4: 155-159, discussion 161.
30. Potters L et al. Examining the role of neoadjuvant androgen deprivation in patients undergoing prostate brachytherapy. J Clin Oncol 2000; 18: 1187-1192.
31. Wallner K, Blasko J, Dattoli M. Prostate Brachytherapy made Complicated, 2nd edn. SmartMedicine, Seattle 2002.
32. Merrick GS et al. Prostate-specific antigen spikes after permanent prostate brachytherapy. Int J Radiat Oncol Biol Phys 2002; 54: 450-456.
33. Stock RG, Stone NN, Cesaretti JA. Prostate-specific antigen bounce after prostate seed implantation for localized prostate cancer: Descriptions and implications. Int J Radiat Oncol Biol Phys 2003; 56: 448-453.
34. Vicini FA et al. An interinstitutional and interspecialty comparison of treatment outcome data for patients with prostate carcinoma based on predefined prognostic categories and minimum follow-up. Cancer 2002; 95: 2126-2135.
35. Sharkey J et al. Brachytherapy vs radical prostatectomy in patients with clinically localized prostate cancer. Curr Urol Rep 2002; 3: 250-257.
36. Kupelian PA et al. Radical prostatectomy, external beam radiotherapy <72 Gy, external beam radiotherapy >72 Gy, permanent seed implantation, or combined seeds/external beam radiotherapy for stage T1-T2 prostate cancer. Int J Radiat Oncol Biol Phys 2002; 54: 38 (61).
37. Ragde H et al. Modern prostate brachytherapy Prostate specific antigen results in 219 patients with up to 12 years of observed follow-up. Cancer 2000; 89: 135-141.
38. Pound CR et al. Natural history of progression after PSA elevation following radical prostatectomy. JAMA 1999; 281: 1591-1597.
39. Henderson A et al. Toxicity and early biochemical outcomes from 125Iodine prostate brachytherapy in the UK. Clin Oncol 2004; 16: 95-104.
40. Ragde H et al. Brachytherapy for clinically localized prostate cancer: results at 7- and 8-year follow-up. Semin Surg Oncol 1997; 13: 438-443.
41. Terk MD, Stock RG, Stone NN. Identification of patients at increased risk for prolonged urinary retention following radioactive seed implantation of the prostate. J Urol 1998; 160: 1379-1382.
42. Beyer DC, Priestley Jr JB. Biochemical disease-free survival following 125I prostate implantation. Int J Radiat Oncol Biol Phys 1997; 37: 559-563.
43. Merrick GS et al. Prophylactic versus therapeutic alpha-blockers after permanent prostate brachytherapy. Urology 2002; 60: 650-655.
44. Merrick GS et al. Temporal resolution of urinary morbidity following prostate brachytherapy. Int J Radiat Oncol Biol Phys 2000; 47: 121-128.
45. Hu K, Wallner K. Urinary incontinence in patients who have a TURP/TUIP following prostate brachytherapy. Int J Radiat Oncol Biol Phys 1998; 40: 783-786.
46. Merrick GS et al. Rectal function following prostate brachytherapy. Int J Radiat Oncol Biol Phys 2000; 48: 667-674.
47. Gelblum DY, Potters L. Rectal complications associated with transperineal interstitial brachytherapy for prostate cancer. Int J Radiat Oncol Biol Phys 2000; 48: 119-124.
48. Augustin H et al. Patient self-reporting questionnaire on urological morbidity and bother after radical retropubic prostatectomy. Eur Urol 2002; 42: 112-117.
49. Bates TS, Wright MP, Gillatt DA. Prevalence and impact of incontinence and impotence following total prostatectomy assessed anonymously by the ICS-male questionnaire. Eur Urol 1998; 33: 165-169.
50. Steineck G et al. Quality of life after radical prostatectomy or watchful waiting. N Engl J Med 2002; 347: 790-796.
51. Potters L et al. Potency after permanent prostate brachytherapy for localized prostate cancer. Int J Radiat Oncol Biol Phys 2001; 50: 1235-1242.
52. Merrick GS et al. Efficacy of sildenafil citrate in prostate brachytherapy patients with erectile dysfunction. Urology 1999; 53: 1112-1116.
53. Stock RG, Kao J, Stone NN. Penile erectile function after permanent radioactive seed implantation for treatment of prostate cancer. J Urol 2001; 165: 436-439.
54. Jani AB, Hellman S. Early prostate cancer: Clinical decision-making. Lancet 2003; 361: 1045-1053.
55. Davis JW et al. Quality of life after treatment for localized prostate cancer: Differences based on treatment modality. J Urol 2001; 166: 947-952.
56. Fulmer BR et al. Prospective assessment of voiding and sexual function after treatment for localized prostate carcinoma: Comparison of radical prostatectomy to hormonobrachytherapy with and without external beam radiotherapy. Cancer 2001; 91: 2046-2055.
57. Ash D et al. ESTRO/EAU/EORTC recommendations on permanent seed implantation for localized prostate cancer. Radiother Oncol 2000; 57: 315-321.
58. Nag S. Brachytherapy for prostate cancer: Summary of American Brachytherapy Society recommendations. Semin Urol Oncol 2000; 18: 133-136.
59. Kestin LL et al. Percentage of positive biopsy cores as predictor of clinical outcome in prostate cancer treated with radiotherapy. J Urol 2002; 168: 1994-1999.
60. Crook J et al. Factors influencing risk of acute urinary retention after TRUS-guided permanent prostate seed implantation. Int J Radiat Oncol Biol Phys 2002; 52: 453-460.
61. Peschel R, Colberg J. Surgery, brachytherapy and external-beam radiotherapy for early prostate cancer. Lancet Oncol 2003; 4: 233-241.